Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston
boston blog main
boston top stories
clinical trials
life sciences
national blog main
rare disease drugs
3
×
dyne therapeutics
fda
myotonic dystrophy type 1
san diego blog main
alexion pharmaceuticals
amyotrophic lateral sclerosis (als)
astellas pharma
atlas venture
audentes therapeutics
autoimmune disorders
avidity biosciences
biotech ipos
bluebird bio
complement system
deals
duchenne muscular dystrophy
facioscapulohumeral muscular dystrophy
gene therapy
generalized myasthenia gravis
immune-mediated necrotizing myopathy
joshua brumm
kaleido biosciences
metacrine
muscular dystrophy
national top stories
new york blog main
nonalcoholic steatohepatitis
ra pharmaceuticals
rare diseases
romesh subramanian
salk institute
san diego top stories
What
drug
3
×
medicines
3
×
dyne
genetic
ipo
muscle
rare
therapeutics
ago
alternative
autoimmune
biotechs
brings
candidate
company
considering
data
deal
developing
disease
diseases
disorders
dyne’s
early
expected
expensive
experimental
eyes
having
humans
ipos
lead
long
million
muscular
pharma
pharmaceuticals
potential
preclinical
ra
Language
unset
Current search:
drug
×
medicines
×
" rare disease drugs "
×
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma